Glycyrrhizin attenuates renal inflammation in a mouse Con A-hepatitis model via the IL-25/M2 axis

References

• Ginès P, Solà E, Angeli P, et al. Hepatorenal syndrome. Nat Rev Dis Primers. 2018;4(1):1. doi: 10.1038/s41572-018-0022-7.
   PubMedGoogle Scholar
• Chen N, Chen X, Ding X, et al. Analysis of the high incidence of acute kidney injury associated with acute-on-chronic liver failure. Hepatol Int. 2018;12(3):262–11. May doi: 10.1007/s12072-018-9866-x.
   PubMed Web of Science ®Google Scholar
• Okamoto T, Nakano Y, Asakura W, et al. Expression of cytokine mRNA in extrahepatic organs in a mouse concanavalin A-hepatitis model. Jpn J Pharmacol. 1998;77(3):219–225.
   PubMedGoogle Scholar
• Wang J, Ren C, Bi W, et al. Glycyrrhizin mitigates acute lung injury by inhibiting the NLRP3 inflammasome in vitro and in vivo. J Ethnopharmacol. 2023;303:115948. doi: 10.1016/j.jep.2022.115948.
   PubMed Web of Science ®Google Scholar
• Takahara T, Watanabe A, Shiraki K. Effects of glycyrrhizin on hepatitis B surface antigen: a biochemical and morphological study. J Hepatol. 1994;21(4):601–609. doi: 10.1016/s0168-8278(94)80108-8.
   PubMed Web of Science ®Google Scholar
• Sato H, Goto W, Yamamura J, et al. Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res. 1996;30(2–3):171–177.
   PubMed Web of Science ®Google Scholar
• Thakur V, Nargis S, Gonzalez M, et al. Role of glycyrrhizin in the reduction of inflammation in diabetic kidney disease. Nephron. 2017;137(2):137–147. doi: 10.1159/000477820.
   PubMed Web of Science ®Google Scholar
• Oh H, Choi A, Seo N, et al. Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on post-contrast acute kidney injury. Sci Rep. 2021;11(1):15625. doi: 10.1038/s41598-021-94928-5.
   PubMed Web of Science ®Google Scholar
• Liu C, Cheng Z, Wang Y, et al. Paeoniflorin exerts a nephroprotective effect on concanavalin A-induced damage through inhibition of macrophage infiltration. Diagn Pathol. 2015;10(1):120. doi: 10.1186/s13000-015-0347-4.
   PubMedGoogle Scholar
• Ginhoux F, Guilliams M. Tissue-resident macrophage ontogeny and homeostasis. Immunity. 2016;44(3):439–449. doi: 10.1016/j.immuni.2016.02.024.
   PubMed Web of Science ®Google Scholar
• Wang D, Xiong M, Chen C, et al. Legumain, an asparaginyl endopeptidase, mediates the effect of M2 macrophages on attenuating renal interstitial fibrosis in obstructive nephropathy. Kidney Int. 2018;94(1):91–101.
   PubMed Web of Science ®Google Scholar
• Guiteras R, Flaquer M, Cruzado JM. Macrophage in chronic kidney disease. Clin Kidney J. 2016;9(6):765–771. doi: 10.1093/ckj/sfw096.
   PubMed Web of Science ®Google Scholar
• Yang Z, Sun D, Yan Z, et al. Differential role for p120-catenin in regulation of TLR4 signaling in macrophages. J Immunol. 2014;193(4):1931–1941. doi: 10.4049/jimmunol.1302863.
   PubMed Web of Science ®Google Scholar
• Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117(5):1155–1166. doi: 10.1172/JCI31422.
   PubMed Web of Science ®Google Scholar
• Deng C, Peng N, Tang Y, et al. Roles of IL-25 in type 2 inflammation and autoimmune pathogenesis. Front Immunol. 2021;12:691559. doi: 10.3389/fimmu.2021.691559.
   PubMed Web of Science ®Google Scholar
• Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001;15(6):985–995. doi: 10.1016/s1074-7613(01)00243-6.
   PubMed Web of Science ®Google Scholar
• Caruso R, Sarra M, Stolfi C, et al. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology. 2009;136(7):2270–2279. doi: 10.1053/j.gastro.2009.02.049.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Monteleone I, Fina D, et al. Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. Inflamm Bowel Dis. 2012;18(3):449–459.
   PubMed Web of Science ®Google Scholar
• Cao Q, Wang C, Zheng D, et al. IL-25 induces M2 macrophages and reduces renal injury in proteinuric kidney disease. J Am Soc Nephrol. 2011;22(7):1229–1239. doi: 10.1681/ASN.2010070693.
   PubMed Web of Science ®Google Scholar
• Huang Q, Niu Z, Tan J, et al. IL-25 elicits innate lymphoid cells and multipotent progenitor type 2 cells that reduce renal ischemic/reperfusion injury. J Am Soc Nephrol. 2015;26(9):2199–2211. doi: 10.1681/ASN.2014050479.
   PubMed Web of Science ®Google Scholar
• Poudel B, Ekperikpe US, Mandal S, et al. Chronic treatment with IL-25 increases renal M2 macrophages and reduces renal injury in obese DAHL salt-sensitive rats during the prepubescent stage. Am J Physiol Renal Physiol. 2023;325(1):F87–F98.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li L, Qi C, et al. Glycyrrhizin alleviates Con A-induced hepatitis by differentially regulating the production of IL-17 and IL-25. Biomed Pharmacother. 2019;110:692–699.
   PubMed Web of Science ®Google Scholar
• Wang X, Liang Y, Wang H, et al. The protective role of IL-36/IL-36R signal in Con A-induced acute hepatitis. J Immunol. 2022;208(4):861–869. doi: 10.4049/jimmunol.2100481.
   PubMed Web of Science ®Google Scholar
• Zhang MZ, Wang X, Wang Y, et al. IL-4/IL-13-mediated polarization of renal macrophages/dendritic cells to an M2a phenotype is essential for recovery from acute kidney injury. Kidney Int. 2017;91(2):375–386.
   PubMed Web of Science ®Google Scholar
• Ye S, Zhu Y, Ming Y, et al. Glycyrrhizin protects mice against renal ischemia–reperfusion injury through inhibition of apoptosis and inflammation by downregulating p38 mitogen-activated protein kinase signaling. Exp Ther Med. 2014;7(5):1247–1252. doi: 10.3892/etm.2014.1570.
   PubMed Web of Science ®Google Scholar
• Lau A, Wang S, Liu W, et al. Glycyrrhizic acid ameliorates HMGB1-mediated cell death and inflammation after renal ischemia reperfusion injury. Am J Nephrol. 2014;40(1):84–95. doi: 10.1159/000364908.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang R, Chen J, et al. High mobility group Box1 inhibitor glycyrrhizic acid attenuates kidney injury in streptozotocin-induced diabetic rats. Kidney Blood Press Res. 2017;42(5):894–904. doi: 10.1159/000485045.
   PubMed Web of Science ®Google Scholar
• Zheng XL, Wu JP, Gong Y, et al. IL-25 protects against high-fat diet-induced hepatic steatosis in mice by inducing IL-25 and M2a macrophage production. Immunol Cell Biol. 2019;97(2):165–177. doi: 10.1111/imcb.12207.
   PubMed Web of Science ®Google Scholar
• Mantani PT, Duner P, Bengtsson E, et al. Interleukin-25 (IL-25) has a protective role in atherosclerosis development in the aortic arch in mice. J Biol Chem. 2018;293(18):6791–6801.
   PubMed Web of Science ®Google Scholar
• Bolisetty S, Zarjou A, Hull TD, et al. Macrophage and epithelial cell H-ferritin expression regulates renal inflammation. Kidney Int. 2015;88(1):95–108.
   PubMed Web of Science ®Google Scholar
• Munro DAD, Hughes J. The origins and functions of tissue-resident macrophages in kidney development. Front Physiol. 2017;8:837. doi: 10.3389/fphys.2017.00837.
   PubMed Web of Science ®Google Scholar
• Kumar S. Cellular and molecular pathways of renal repair after acute kidney injury. Kidney Int. 2018;93(1):27–40. doi: 10.1016/j.kint.2017.07.030.
   PubMed Web of Science ®Google Scholar
• Cao Q, Wang Y, Harris DC. Pathogenic and protective role of macrophages in kidney disease. Am J Physiol Renal Physiol. 2013;305(1):F3–11. doi: 10.1152/ajprenal.00122.2013.
   PubMed Web of Science ®Google Scholar
• Trombetta AC, Soldano S, Contini P, et al. A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. Respir Res. 2018;19(1):186. doi: 10.1186/s12931-018-0891-z.
   PubMedGoogle Scholar
• Wanderley CW, Colón DF, Luiz JPM, et al. Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner. Cancer Res. 2018;78(20):5891–5900. doi: 10.1158/0008-5472.CAN-17-3480.
   PubMed Web of Science ®Google Scholar
• Wu L, Tang H, Zheng H, et al. Multiwalled carbon nanotubes prevent tumor metastasis through switching M2-polarized macrophages to M1 via TLR4 activation. J Biomed Nanotechnol. 2019;15(1):138–150. doi: 10.1166/jbn.2019.2661.
   PubMed Web of Science ®Google Scholar